IRCT20200825048515N58 IRCT 2022-09-05 Esfahan University of Medical Sciences Evaluation of therapeutic effects of adding memantine to stimulants in children with attention deficit hyperactivity disorder Evaluation of therapeutic effects of adding memantine to stimulants in children with attention deficit hyperactivity disorder 2022-09-23 anticipated 80 Complete https://irct.ir/trial/65611 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The method is permuted block randomization. In this way, first using online software (sealed envelope), a sequence of random numbers will be created and by the same software, the generated numbers will be divided into 40 blocks of 2. An equal number in each block will be 1 item from the intervention group and 1 item from the control group. So by doing each block, 2 patients (equally) will be assigned to each group, Blinding description: In this study, two drugs, memantine, and placebo are pre-prepared by the pharmacist in the same shape and color, placed in coded packages, and delivered to the researcher. She prescribes them without knowing the type of each drug. Also, the patients, the investigator, the person recording the clinical and basic information of the patients as well as the statistical analyst will not be aware of the type of intervention. 3 Attention-deficit hyperactivity disorder (ADHD). Intervention 1: Intervention group: Patients in this group receive their routine treatment. In addition, they will be treated with memantine. The prescribed dose in children is based on weight, so that for children weighing more than 60 kg, the maximum dose is 15 mg/day, and for children weighing 39 to 60 kg, the maximum dose is 9 mg/day, and for children weighing 20 to 39 kg, the maximum dose is 6 mg/day and with a weight of less than 20 kg, a maximum dose of 3 mg/day is prescribed. The duration of the study will be one month after stabilizing the dose of memantine based on weight or the maximum dose tolerated by the patient. Intervention 2: Control group: patients in this group receive their routine treatment. In addition, they will be prescribed the same as the placebo intervention group. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information